Rationale for combination use of targeted agents in ovarian cancer: Do we have one?

Cancer

Volumn 113, Issue 4, 2008, Pages 665-667

  Coleman, Robert L ^a   Kohn, Elise C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; ENDOTHELIAL CELL GROWTH FACTOR; ERLOTINIB; GEFITINIB; IMATINIB; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM DERIVATIVE; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ASCITES; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG TARGETING; EDEMA; EFFUSION; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NOTE; OVARY CANCER; OVERALL SURVIVAL; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; TARGET CELL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PIPERAZINES; PYRIMIDINES; TAXOIDS;

EID: 50249162119     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23604     Document Type: Note

References (18)

1. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786-2792.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
3. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer. 2003;3:421-422.
4. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125-134.
7. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
8. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD 1839) (Iressa) tablets. Oncologist. 2003;8:303-306.
9. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10: 1212-1218.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
11. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
12. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res. 2005;11:3032-3037.
13. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847-855.
14. Blank SV, Chang R, Muggia F. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology (Williston Park). 2005;19:553-559; discussion 560-562, 567.
15. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539-5548.
16. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer. 2008;113:723-732.
17. Posadas EM, Kwidcowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007;110:309-317.
18. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is anti-angiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005; 23:939-952.